Dapsone NDC 67046-1477

NDC codes

FDA NDC Directory

Product NDC (as listed)67046-1477Labeler and product segments. Claims need a package NDC.

Product NDC at billing width67046-1477Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
67046-1477-3	67046147703	30 TABLET in 1 BLISTER PACK (67046-1477-3)Marketed from Jan 31, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dapsone
Generic name (nonproprietary): dapsone
Active ingredients: Dapsone — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Coupler LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207165
Marketing start: Jan 31, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Sulfones (Chemical structure)
Identifiers: Product ID 67046-1477_2d018cbb-21a4-5f63-e063-6394a90aadc3SPL ID 2d018cbb-21a4-5f63-e063-6394a90aadc3SPL set ID 2d018cbb-21b2-5f63-e063-6394a90aadc3RxCUI 197557UNII 8W5C518302
Pharmacologic class: Sulfone

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N467046147703 followed by a unit qualifier and the quantity

Package 67046-1477-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 31, 2025.

Indications (excerpt from the label)

INDICATIONS & USAGE Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)